LBA66 Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
N Girard, SP Aix, S Cedres, T Berghmans… - Annals of …, 2021 - annalsofoncology.org
Background Thymic malignancies are rare intrathoracic tumors which still represent a
therapeutic challenge in the advanced/metastatic setting, with limited treatment options after
the failure of platinum-based chemotherapy. Methods NIVOTHYM is the first international
multicenter phase II, 2-cohort, single-arm trial evaluating the use of nivolumab (240 mg IV
Q2 weeks)+/-ipilimumab (1mg/kg IV Q6 weeks) in patients (pts) with advanced/relapsed type
B3 thymoma or thymic carcinoma, after exposure of platinum-based chemotherapy. Primary …
therapeutic challenge in the advanced/metastatic setting, with limited treatment options after
the failure of platinum-based chemotherapy. Methods NIVOTHYM is the first international
multicenter phase II, 2-cohort, single-arm trial evaluating the use of nivolumab (240 mg IV
Q2 weeks)+/-ipilimumab (1mg/kg IV Q6 weeks) in patients (pts) with advanced/relapsed type
B3 thymoma or thymic carcinoma, after exposure of platinum-based chemotherapy. Primary …
Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial
N Girard, SP Aix, S Cedres, T Berghmans, S Burgers… - ESMO open, 2023 - Elsevier
Background Thymic malignancies are rare intrathoracic tumors, which may be aggressive
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic
setting, with limited treatment options after the failure of first-line platinum-based
chemotherapy. They are frequently associated with autoimmune disorders that also impact
oncological management. Materials and methods NIVOTHYM is an international,
multicenter, phase II, two-cohort, single-arm trial evaluating the activity and safety of …
and difficult to treat. They represent a therapeutic challenge in the advanced/metastatic
setting, with limited treatment options after the failure of first-line platinum-based
chemotherapy. They are frequently associated with autoimmune disorders that also impact
oncological management. Materials and methods NIVOTHYM is an international,
multicenter, phase II, two-cohort, single-arm trial evaluating the activity and safety of …
以上显示的是最相近的搜索结果。 查看全部搜索结果